The trial will study 8,000 patients with stable ischemic heart disease and moderate to sever ischemia, the release said. The strategies to be investigated are whether an early invasive strategy with cardiac catheterization followed by revascularization and optimal medical therapy produces better results than a simply using OMT. It will also assess whether the invasive strategy improves “angina-related quality of life.”
Read the news release on NYU Langone Medical Center.
Related Articles on Hospital Cardiology:
Virginia’s Valley Health Acquires Cardiology Group
Retired Cardiologist Convicted, Faces up to 35 Years in Prison for Unnecessary Stents, Fraudulent Billing
Ohio Heart and Vascular Center Opens Heart Failure Clinic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
